You are here
Stewart Graham, PhD
Areas of Interest:
Alzheimer's disease, neurodegeneration, biochemical profiling, brain, biomarkers, mass spectrometry, metabolomics, multivariate analysis, 1H NMR
Biography & Research:
Dr. Stewart Graham is from Northern Ireland where he completed his B.Sc. (Hons) in Biochemistry, M.Sc. in Bimolecular Structure and Function and Ph.D. in Metabolomics at Queen’s University Belfast between 2000 and 2009. Following the completion of his Ph.D., Dr. Graham was employed as a post-doctoral research fellow within the School of Biological Sciences (2009-2011) where he employed his skills as a metabolomicist to identify diagnostic markers of food fraud. In his free time, Dr. Graham actively pursued his own research interests which included the biochemical profiling of transgenic mouse models of Alzheimer’s disease, laying the groundwork for funding from the Alzheimer’s Research Trust UK to continue his research into neurodegenerative disease. From 2011-2014, Dr. Graham worked as an Alzheimer’s Research Trust post-doctoral fellow, where he successfully applied high resolution mass spectrometry and nuclear magnetic resonance for the first ever reported biochemical profiling of post-mortem human brain from Alzheimer’s disease sufferers. In 2014, Dr. Graham was appointed as a lecturer at Queen’s University Belfast, a position which he held in an honorary role until 2017. In January 2014, he was employed as the Director of Metabolomics Research at Beaumont Health. Further, Dr. Graham was appointed Assistant Professor in 2016 at Oakland University-William Beaumont School of Medicine prior to his promotion to Associate Professor in July of 2020. His current research interests focus predominantly on neurodegenerative disease to include Alzheimer’s, Parkinson’s and Huntington’s disease and has resulted in more than 60 peer-reviewed manuscripts. Dr. Graham’s research is currently funded by a variety of agencies including the NIH, the Alzheimer’s Association and the Michael J. Fox Foundation (MJFF). He serves regularly on various peer-review groups including NIH study sections, the Alzheimer’s Association, and the MJFF in addition to numerous International funding institutions. His overarching goals as a neuroscientist are not only to identify early diagnostic/predictive biomarkers of the aforementioned diseases but to better understand their underling etiopathogenesis. By combining his interests in mechanism and diagnostics, his principal goal is to get the “Right drug, to the Right person at the Right time”.